Pharvaris (PHVS) News Today $22.29 +1.25 (+5.94%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Oppenheimer Remains a Buy on Pharvaris (PHVS)November 15, 2024 | markets.businessinsider.comPharvaris Advances in HAE Treatment with Strong FinancialsNovember 14, 2024 | markets.businessinsider.comPharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNovember 13, 2024 | globenewswire.comPharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceNovember 12, 2024 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)November 12, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comPharvaris’s Promising Developments in HAE Treatment Drive Buy RatingOctober 26, 2024 | markets.businessinsider.comPharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingOctober 24, 2024 | markets.businessinsider.comPharvaris (PHVS) Receives a Buy from Morgan StanleyOctober 22, 2024 | markets.businessinsider.comPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsOctober 16, 2024 | globenewswire.comPharvaris to Host Virtual Investor Event on October 23, 2024October 15, 2024 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Pharvaris (PHVS)October 15, 2024 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)October 15, 2024 | markets.businessinsider.comPharvaris (PHVS) Gets a Buy from Morgan StanleyOctober 7, 2024 | markets.businessinsider.comPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership WorkshopOctober 3, 2024 | globenewswire.comNovo Holdings A S Has $32.43 Million Stock Position in Pharvaris (NASDAQ:PHVS)Novo Holdings A S raised its holdings in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 47.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,725,000 shares of the company's stock after purchasing anSeptember 30, 2024 | marketbeat.comMorgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)September 24, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Pharvaris N.V. (PHVS) with Buy RecommendationSeptember 21, 2024 | msn.comPromising Oral HAE Treatment Deucrictibant Poised for Blockbuster Sales: A Buy Rating AnalysisSeptember 19, 2024 | markets.businessinsider.comBuy Rating on Pharvaris: Promising Results and Strategic Market Position for HAE TreatmentSeptember 10, 2024 | markets.businessinsider.comPharvaris Provides Business Update and Expands Development Program for DeucrictibantSeptember 5, 2024 | globenewswire.comPharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024September 5, 2024 | globenewswire.comPharvaris Presents Data at the Bradykinin Symposium 2024September 5, 2024 | globenewswire.comMorgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)September 4, 2024 | markets.businessinsider.comDeucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin SymposiumAugust 28, 2024 | globenewswire.comMorgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)August 27, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08August 27, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.2%Pharvaris (NASDAQ:PHVS) Shares Up 5.2%August 26, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 2.4%Pharvaris (NASDAQ:PHVS) Shares Down 2.4%August 23, 2024 | marketbeat.comMorgan Stanley Remains a Buy on Pharvaris (PHVS)August 20, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS), Pharvaris (PHVS) and United Therapeutics (UTHR)August 20, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Pharvaris (PHVS)August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Phase 3 Trial Prospects and Solid Financial PositionAugust 15, 2024 | markets.businessinsider.comPharvaris N.V.: Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.dePharvaris Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Up 5.1%Pharvaris (NASDAQ:PHVS) Trading Up 5.1%August 5, 2024 | marketbeat.comPharvaris N.V. (9EN.SG)July 19, 2024 | uk.finance.yahoo.comPharvaris Announces Annual Meeting of ShareholdersJune 11, 2024 | globenewswire.comPharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesJune 4, 2024 | globenewswire.comPharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesMay 13, 2024 | globenewswire.comPharvaris N.V.: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | finanznachrichten.dePharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy RatingMay 10, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pharvaris (PHVS)May 9, 2024 | markets.businessinsider.comPHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024May 9, 2024 | msn.comPharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Up 8%Pharvaris (NASDAQ:PHVS) Stock Price Up 8%April 22, 2024 | marketbeat.comMorgan Stanley Reiterates "Overweight" Rating for Pharvaris (NASDAQ:PHVS)Morgan Stanley reaffirmed an "overweight" rating and issued a $34.00 target price on shares of Pharvaris in a report on Monday.April 22, 2024 | marketbeat.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | finance.yahoo.com Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼-1.500.49▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼11▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alvotech News biote News BriaCell Therapeutics News Clever Leaves News Fortress Biotech News GeoVax Labs News LAVA Therapeutics News Mainz Biomed News Procaps Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
